公开(公告)号：US20250034133A1

公开(公告)日：2025-01-30

申请号：US18708755

申请日：2022-11-11

Applicant: INSILICO MEDICINE IP LIMITED

Inventor： Jianping Wu ,  Luoheng QIN ,  Jinxin LIU ,  Yingtao LIU

IPC: C07D471/04 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/542 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04

Abstract: Provided are small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. Further provided are methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancers.

公开(公告)号：US20240150374A1

公开(公告)日：2024-05-09

申请号：US18507566

申请日：2023-11-13

Applicant: Insilico Medicine IP Limited

Inventor： Xin CHENG ,  Luoheng QIN ,  Feng REN

IPC: C07D498/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

CPC classification number: C07D498/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: Described herein are KAT6A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KAT6A.

公开(公告)号：US20230192667A1

公开(公告)日：2023-06-22

申请号：US18110517

申请日：2023-02-16

Applicant: Insilico Medicine IP Limited

Inventor： Xin CHENG ,  Yingtao LIU ,  Luoheng QIN ,  Feng REN ,  Jianping WU

IPC: C07D403/14 ,  C07D403/04 ,  C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  A61P35/00

CPC classification number: C07D403/14 ,  A61P35/00 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.

公开(公告)号：US20250026754A1

公开(公告)日：2025-01-23

申请号：US18709234

申请日：2022-11-11

Applicant: INSILICO MEDICINE IP LIMITED

Inventor： Jianping Wu ,  Luoheng QIN ,  Jinxin LIU

IPC: C07D471/04 ,  A61K31/444 ,  A61K31/506 ,  A61P35/00

Abstract: Provided are small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. Provided are methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.

公开(公告)号：US20240116899A1

公开(公告)日：2024-04-11

申请号：US18237140

申请日：2023-08-23

Applicant: Insilico Medicine IP Limited

Inventor： Xin CHENG ,  Yingtao LIU ,  Luoheng QIN

IPC: C07D403/14 ,  A61P35/00 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D403/14 ,  A61P35/00 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.

公开(公告)号：US20250066348A1

公开(公告)日：2025-02-27

申请号：US18708686

申请日：2022-11-11

Applicant: INSILICO MEDICINE IP LIMITED

Inventor： Jianping Wu ,  Luoheng QIN ,  Jinxin LIU

IPC: C07D471/04 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  C07D487/04

Abstract: Provided herein are small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. Further provided herein are methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.

公开(公告)号：US20240109880A1

公开(公告)日：2024-04-04

申请号：US18486369

申请日：2023-10-13

Applicant: Insilico Medicine IP Limited

Inventor： Xin CHENG ,  Luoheng QIN ,  Feng REN

IPC: C07D413/14 ,  C07D498/04 ,  C07D413/06 ,  C07D413/12 ,  C07D417/14 ,  C07D417/12 ,  C07D417/06

CPC classification number: C07D413/14 ,  C07D498/04 ,  C07D413/06 ,  C07D413/12 ,  C07D417/14 ,  C07D417/12 ,  C07D417/06

Abstract: Described herein are KAT6A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KAT6A.